Dielectric Spectroscopy: Choosing the Right Approach - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Dielectric Spectroscopy: Choosing the Right Approach
This tutorial paper is meant to aid in dielectric-sensor selection

Pharmaceutical Technology
Volume 9, Issue 32, pp. 8293

The US Food and Drug Administration's process analytical technology (PAT) initiative reflects the need for improved quality control in the pharmaceutical industry. As the complexity of pharmaceutical products increases, quality control becomes more costly and difficult. New analytical instrumentation should be developed to address the quality control problems associated with more complex pharmaceutical products. Dielectric spectroscopy, one of many process analytical technologies, has been used for several decades. As any other technology, it is continuously evolving. New instrumentation, algorithms, and materials broaden the applicability and capabilities of this method. Selecting the optimal architecture for a sensing system intended for each specific application requires a good understanding of main principles and engineering trade-offs common for this field. This article is written primarily for field practitioners who need to make a judicious choice of the best measurement technique for their application. Main principles and design features of dielectric sensors are discussed in the framework of pharmaceutical applications.

The range of potential applications of dielectric spectroscopy is quite broad. Virtually any physical process change leads to changes in dielectric properties of samples. Process variability is a primary concern for the pharmaceutical industry (1). Exposure to mechanical and thermal stress can cause a change in the physical properties of pharmaceuticals. Such variations are important to control because physical properties generally determine the efficacy of the drug. For instance, tablet coatings control the rate of drug delivery within the body of a patient (2–5) and influence the bioavailability of the drug. In addition, coatings protect the active ingredient from chemically harsh environments in the body (6). Similarly, API content in a given sample determines the potency of the drug. The drying process of pharmaceuticals is critical because 70% of global granulated pharmaceutical product is made using wet granulation (7). In wet granulation, liquid binding gels are used to facilitate bonding between active ingredients. At this stage, it is important to measure moisture because specific moisture levels are required for the formation of the correct-size granules. Further, in high-shear wet granulation methods, incorrect moisture levels can lead to a process-induced transformation (PIT) (8). In these transformations, the properties of the active ingredients can change, resulting in reduced efficacy.

Overview of sensing methods

Process analytical technologies. A number of sensing technologies can be used to detect physical properties of pharmaceuticals. Most commonly used technologies include near infrared spectroscopy (NIR) and Raman spectroscopy. Digital imaging methods, optical methods, and dielectric spectroscopy also are used to measure various physical properties.

NIR spectroscopy is widely used to measure API content, distribution of contaminants, moisture content, and polymorphism determination (9). Similarly, Raman spectroscopy has demonstrated success in measuring pharmaceutical reaction times, polymorphism, and differences between solid-state forms (8).

Digital imaging methods are used to monitor particle size in pharmaceutical powders (10). Optical methods have been used for inspection of tablet coatings (6), measurement of constituent concentration of pharmaceutical powder mixtures (11), and quantitative analyses of ascorbic acid in pharmaceuticals (11, 12). For example, laser induced breakdown spectroscopy (LIBS) is used to measure coating thickness of tablets (13).

Previous work using dielectric spectroscopy. Dielectric spectroscopy is a promising method to study physical properties of pharmaceutical solutions, colloids, microcapsules, gels, and emulsions. Craig provides a thorough review of these applications (14), which are summarized in this section.

Pharmaceutical solutions are important because the solubility of a drug in the solvent directly influences its rate of disassociation in the body, which in turn impacts bioavailability. Dielectric properties such as the static dielectric constant of solutions has been used to study the solubility of cosolvent systems, reaction rates of pharmaceutical solutions, and drug stability (14).

Colloids are two-phase systems that consist of particles suspended in a medium. Each particle in a colloidal solution has an electrical layer surrounding it that determines the stability of the system by affecting the aggregation or disassociation of colloidal particles. As a result of these forces, dielectric response of colloidal solutions provides information about particle size in the colloidal solutions. For example, a study conducted by Paul and Vogey suggested an inverse-square dependency between particle radius and dielectric relaxation frequency of the medium (15). This relationship is illustrated in the following equation:

in which D is the diffusion coefficient of counterions with a particle radius of a, and f c is the loss peak frequency. The inverse-square relationship between relaxation frequency and particle radius was confirmed in a subsequent study (16).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here